The FDA has granted fast-track status to the development of psychedelic medications, reportedly in response to an executive order. The move is expected to expedite the review of certain psychedelic drugs for mental health treatment, with some outlets specifying that three drugs or studies are involved. The specific drugs mentioned include psilocybin and methylone, and at least three companies are set to receive vouchers to aid in the fast-tracked review process.